FIG. 7.

Flow-mediated dilation changes in response to inhibitors/scavengers of ROS/RNS. There is a significant decrease in FMD in aging, reversed by SVF and ADSC therapy (a). During youth, FMD is inhibited by L-NAME inhibition of eNOS NO production, but not uric acid or catalase (b). During aging, there are no differences in FMD with preincubation of L-NAME, uric acid, or catalase (c). With SVF and ADSC therapy, FMD is attenuated with L-NAME and uric acid scavenging of peroxynitrite (d, e). Significance determined as p < 0.05 with two-way repeated-measures ANOVA with the Holm–Sidak post hoc analysis. L-NAME, N-Nitro-L-arginine methylester.